Lymphoblastic lymphoma.
Recent advances in the unique clinicopathologic entity of lymphoblastic lymphoma (and its variants) are discussed in this article, which details the natural history, molecular biology, prognosis, and outcome with various chemotherapy regimens. Improved outcome with the newer intensive chemotherapy regimens and the role of modalities such as autologous intensification, allogeneic bone marrow transplant, and radiotherapy are discussed.
Thomas
D A
DA
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. debthomas@mdanderson.org
Kantarjian
H M
HM
D000293:Adolescent; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001752:Blast Crisis / Q000401:mortality; D016026:Bone Marrow Transplantation; D002173:Cancer Care Facilities / Q000706:statistics & numerical data; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015993:Life Tables; D008297:Male; D008482:Mediastinum / Q000528:radiation effects; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D013781:Texas / Q000453:epidemiology; D016896:Treatment Outcome
D011948:Receptors, Antigen, T-Cell